The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis' more than $2 million gene therapy Zolgensma was manipulated, but the agency believes the treatment should remain on the market.
from Reuters: Health News https://ift.tt/2ZD7gFD
No comments:
Post a Comment